Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target entry refers to the indirect activation of multiple endogenous growth factor receptors, a process frequently termed receptor tyrosine kinase (RTK) transactivation. In this mechanism, an external stimulus—often the activation of a G protein-coupled receptor (GPCR)—triggers intracellular signaling pathways that activate membrane-bound metalloproteinases, such as ADAM (A Disintegrin and Metalloproteinase) family members (Higashiyama et al., 2008, Cancer Science). These enzymes then cleave and release membrane-anchored pro-ligands, such as pro-epidermal growth factor (pro-EGF) or transforming growth factor-alpha (TGF-alpha). The released mature ligands subsequently bind to and activate their respective growth factor receptors, leading to downstream signaling cascades like the MAPK/ERK or PI3K/Akt pathways (Ohtsu et al., 2006, Arteriosclerosis, Thrombosis, and Vascular Biology). This indirect activation plays a critical role in physiological processes such as cell proliferation and wound healing, but it is also a major driver in pathological states including cancer progression, cardiac hypertrophy, and vascular remodeling. Therapeutic strategies targeting this process include the use of RTK inhibitors, monoclonal antibodies against ligands, or metalloproteinase inhibitors to prevent ligand shedding (IUPHAR/BPS Guide to Pharmacology).
Indirect activation occurs when an initial stimulus (typically G protein-coupled receptor activation) triggers the proteolytic cleavage of membrane-anchored pro-ligands by metalloproteinases (e.g., ADAM17). The liberated ligands then bind to and activate their cognate growth factor receptors (e.g., EGFR) in an autocrine or paracrine fashion (Gschwind et al., 2001, Nature Reviews Cancer; Prenzel et al., 1999, Nature).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multiple endogenous growth factor receptors (indirect activation via released ligands) (RTK transactivation).